Chimigen Bio

Chimigen Biomedical (Chengdu) Co., Ltd. (凯米生物), in Tianfu International Bio-Town, Chengdu, China, was founded in June 2021, according to the company, and runs a US subsidiary, ChimiVac, in New York, which sponsors its US trial. Its SynNeogen platform uses an Fc fusion design to deliver multi-epitope payloads directly to dendritic cells to activate CD4 and CD8 T cells, which the company calls immune priming therapy. The lead cancer product KMV002 (IPT-PAP), a vaccine against prostatic acid phosphatase for metastatic castration-resistant prostate cancer, received FDA IND clearance in July 2026, entered an early-phase clinical trial in September 2026 and received FDA Fast Track designation in October 2026, according to the company. A second product, SN2001, is in a phase 1 study in Australia for chronic hepatitis B, and the pipeline lists HBV-positive liver cancer and undisclosed programmes in triple-negative breast and digestive cancers. Its first-ever registry study, NCT07059403, posted in July 2025, is not a cancer study as far as the registry data read show; its first registered cancer trial, NCT07866300 (KMV002), was posted on ClinicalTrials.gov in October 2026. The company states it has closed about USD 40 million in financing, including a Pre-Series A round of more than RMB 100 million listed among its 2025 milestones.